Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Buys $13,064.70 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 3,959 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was bought at an average cost of $3.30 per share, with a total value of $13,064.70. Following the acquisition, the insider owned 82,556 shares of the company’s stock, valued at approximately $272,434.80. The trade was a 5.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Price Performance

NASDAQ SHPH opened at $3.65 on Friday. The stock’s fifty day moving average price is $5.69 and its 200 day moving average price is $10.59. Shuttle Pharmaceuticals Holdings, Inc. has a 1 year low of $2.90 and a 1 year high of $55.90. The company has a market cap of $2.34 million, a price-to-earnings ratio of -0.08 and a beta of 0.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ikarian Capital LLC acquired a new stake in Shuttle Pharmaceuticals during the 4th quarter worth about $124,000. Geode Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at about $26,000. Connective Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals in the 3rd quarter valued at about $357,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals in the 4th quarter valued at about $37,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .